NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Having skipped the early June ASCO meeting because of the need to
have all hands on deck, NWBO's Marnix Bosch finds the time to present on
June 16 at NYAS, a 15 minute Industry Blitz session entitled "Next Generation
Dendritic Cell Treatments To Improve Anti-Tumor Responses". Could that imply that
NWBO perhaps expects MAA approval to arrive before June 16 because even
a 15 minute presentation may require much time and effort if all hands are
still required to be on deck.

Furthermore, wouldn't you think that when MB talks about the tumor response
efficacy of the next generation of dendritic cells, he would have an advantage if
the MHRA had already submitted its MAA approval that underlines that the first
generation of dendritic cells already possesses a substantial degree of efficacy?

Bottom line: Is MB's presentation suggestive of an MAA approval before June 16?